Siemens Healthineers inks data sharing deal with Blue Earth to bolster development of prostate cancer AI
Blue Earth Diagnostics has reached a deal with Siemens Healthineers to share clinical data that will further the development of AI algorithms within the field of prostate cancer imaging, the companies announced on Wednesday.
Specifically, Blue Earth will be sharing anonymized clinical data from its Phase 3 Lighthouse trial involving the use of PET imaging agent Posluma (flotufolastat F 18). For its part, Siemens plans to use the data to inform the development of algorithms for prostate cancer image quantification and interpretation across its PET/CT imaging software.
“Blue Earth Diagnostics is committed to helping men with prostate cancer across the care continuum, and we recognize the importance of AI in advancing healthcare,” Blue Earth CEO David Gauden said in a statement. “AI-based algorithms have the potential to streamline the PET/CT analytical workflow for hospitals and imaging centers by efficiently providing physicians with information critical to patient management and care.”
Bruce Spottiswoode, PhD, director of clinical applications research for Siemens Healthineers, also commented on the partnership, further detailing exactly how the data will be utilized.
“We believe that the Lighthouse trial data will be enormously helpful in tailoring our AI technology to support the quantification and clinical interpretation of Polusma PET/CT images and are pleased to collaborate with Blue Earth Diagnostics on this data-sharing agreement,” Spottiswoode said. “The neural networks we are using have been shown to learn radiotracer-specific PET uptake, and we expect them to more efficiently identify clinically relevant features in 18F-flotufolastat images.”
Posluma is a radiohybrid prostate-specific membrane antigen (PSMA)-targeted PET imaging agent. The primary goal of the Lighthouse trial was to investigate the agent's the safety and efficacy in men with newly diagnosed prostate cancer ranging from intermediate-risk to very high-risk. In a separate trial (Spotlight), Posluma’s utility was evaluated in men with suspected prostate cancer recurrence.
Posluma became commercially available in June 2023.
Read the full release here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.